Holden Comprehensive Cancer Center
Holden Comprehensive Cancer Center
News Article | April 2, 2017
Cancer is a huge obstacle and challenge in the medical world and numerous studies have been done in order to find ways to cure or treat the deadly disease. Some researchers focus on developing drugs that would help patients cope with the harsh effects of chemotherapy, while others look into natural treatments. Tech Times reported on March 24 that a doctor stumbled upon a cure for sepsis and the key is vitamin C. We also reported on March 27 that researchers from the University of Salford Manchester tested different natural substances on cancer stem cells and found that vitamin C seems the most promising in obliterating them. Now a team of researchers from the University of Iowa released the results of their clinical trials and it backs up the vitamin C claim. A team of researchers from the Holden Comprehensive Cancer Center at the University of Iowa looked into the effect of vitamin C in cancer cells, specifically, brain cancer glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). The trials tested the idea that a regular high dose of vitamin C is a safe and effective anti-cancer agent when combined with chemotherapy and other radiation treatments. The researchers also focused on two specific forms of cancer that have the least improvement in terms of treatment. "These two diseases really haven't had a significant improvement in outcomes for two or three decades," study author and UI assistant professor of radiation oncology Bryan Allen said. There's a saying that anything in excess is bad for the body, but it seems the human body makes an exception when it comes to fighting cancer. This is because the dosage of vitamin C that is delivered intravenously is actually 1,000 times higher than the concentration a healthy person has in their blood stream, which is about 70 micromolar. How so? The target is to get the cancer patient's blood to have up to 20,000 micromolar of vitamin C. What happens is that the high concentration of vitamin C messes up the cancer cell metabolism by disrupting the iron levels in the cells. This, in turn, causes excess iron to react to the vitamin C and generate free radicals that can weaken and kill DNA. When this happens, the chemotherapy and radiation can easily kill the cancer cells. The best part is that the trials showed no serious side effects to the patients who participated and there was also an overall increase in the survival rate. The research, titled "O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate," was published in the journal Cancer Cell on March 30. It contains the results of the first phase of the clinical trials, as well as a small portion of the Phase II results. "Results look promising but we're not going to know if this approach really improves therapy response until we complete these phase II trials," Allen said. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.
News Article | September 18, 2017
University of Iowa Holden Comprehensive Cancer Center and Mayo Clinic have received a five-year, $12.4 million grant renewal from the National Cancer Institute (NCI) to continue the Specialized Program of Research Excellence (SPORE) for lymphoma research. The renewal was based on a highly competitive process of peer review conducted by cancer researchers from across the country. The University of Iowa/Mayo Clinic Lymphoma SPORE is a highly productive research collaboration focused on developing new approaches to the prevention, detection, and treatment of lymphoma. First funded in 2002 and competitively renewed in 2007, 2012, and now again in 2017, it is the nation's longest-standing lymphoma SPORE and has now received more than $46 million from the NCI. "We are thrilled to have our Lymphoma SPORE renewed for another five years," says George Weiner, MD, director and principal investigator of the SPORE at the University of Iowa and director of Holden Comprehensive Cancer Center. "It is particularly exciting to see advances we have made being applied worldwide to improve patient care." SPORE funds support four major research projects, four shared research cores, clinical trials, early pilot projects, and new investigators in lymphoma research taking place at Holden Comprehensive Cancer Center and Mayo Clinic Cancer Center. "It is gratifying to see other inter-institutional research groups use the Iowa-Mayo collaborative model to accelerate progress by working across institutions," Weiner says. "Working with outstanding collaborators and staff here at the University of Iowa and at Mayo Clinic on the Lymphoma SPORE has been one of the great pleasures of my career, and I look forward to another five years of close collaboration, and, most importantly, bringing research advances forward so they help patients." "We are grateful to the NCI to receive renewal of our Lymphoma SPORE that is conducted with our colleagues at the University of Iowa," says Thomas Witzig, MD, SPORE director at Mayo Clinic, who received his internal medicine training at the University of Iowa. "This five-year grant will continue our quest to understand why patients get lymphoma and will be providing our patients opportunities for exciting new therapies." Both institutions have extensive experience in lymphoma research, from basic investigation through the performance of innovative clinical trials. The two institutions also work together on the epidemiology of lymphoma. The reviewers commended multiple components of the University of Iowa/Mayo Clinic collaboration, including a supportive scientific environment in both cancer centers that encourages creative, productive research that has resulted in more than 150 papers published in the last funding cycle. The reviewers also noted the SPORE collaboration's high rate of success in funding productive developmental research work and fostering careers in translational lymphoma research. The SPORE team's work includes translational and clinical studies exploring the potential of treatments that stimulate the immune system to treat lymphoma, clinical trials targeting lymphoma-specific signaling pathways, discovery of gene mutations in cell-signaling pathways that contribute to development of lymphoma, identification of key interactions between lymphoma cells and their microenvironment that can be disrupted to make the lymphoma cells more vulnerable to chemotherapies, and investigation into biomarkers that could have a significant impact on management of lymphoma for individual patients. The research team has worked with more than 7,000 patient volunteers to understand how genetic makeup and other factors determine outcomes in patients with lymphoma. University of Iowa faculty and Holden Comprehensive Cancer Center members involved in the SPORE come from the Colleges of Medicine, Pharmacy, Public Health, and Liberal Arts and Sciences and include Weiner, Gail Bishop, Brian Link, Brian Smith, Umar Farooq, Aliasger Salem, Sergei Syrbu, and numerous other faculty and staff. To learn more about the lymphoma SPORE, visit uihc.org/lymphoma-spore. Holden Comprehensive Cancer Center is Iowa's only National Cancer Institute-designated comprehensive cancer center and treated nearly 24,000 unique cancer patients in fiscal year 2016. University of Iowa Health Care is the state's only comprehensive academic medical center, dedicated to providing world-class health care and health-related outreach services to all Iowans. Based in Iowa City, UI Health Care includes University of Iowa Hospitals and Clinics, the University of Iowa Roy J. and Lucille A. Carver College of Medicine, and University of Iowa Physicians, the state's largest multispecialty physician group practice.
Zhu Y.,Holden Comprehensive Cancer Center |
Mapuskar K.A.,University of Iowa |
Marek R.F.,University of Iowa |
Xu W.,University of Iowa |
And 6 more authors.
Toxicological Sciences | Year: 2013
Recent analysis of air samples from Chicago and Lake Michigan areas observed a ubiquitous airborne polychlorinated biphenyl (PCB) congener, 3,3'-dichlorobiphenyl (PCB11). Our analysis of serum samples also revealed the existence of hydroxylated metabolites of PCB11 in human blood. Because PCBs and PCB metabolites have been suggested to induce oxidative stress, this study sought to determine whether environmental exposure to PCB11 and its 4-hydroxyl metabolite could induce alterations in steady-state levels of reactive oxygen species (ROS) and cytotoxicity in immortalized human prostate epithelial cells (RWPE-1). This study also examines if antioxidants could protect the cells from PCB11-induced cytotoxicity. Exponentially growing RWPE-1 cells were exposed to PCB11 and its metabolite, 3,3'-dichlorobiphenyl-4-ol (4-OH-PCB11), as well as an airborne PCB mixture resembling the Chicago ambient air congener profile, every day for 5 days. Results showed that 4-OH-PCB11 could significantly induce cell growth suppression and decrease the viability and plating efficiency of RWPE-1 cells. 4-OH-PCB11 also significantly increased steady-state levels of intracellular superoxide, O. 2 •-, as well as hydroperoxides. Finally, treatment with the combination of polyethylene glycol-conjugated CuZn superoxide dismutase and catalase added 1h after 4-OH-PCB11 exposures, significantly protected RWPE-1 cells from PCB toxicity. The results strongly support the hypothesis that exposure to a hydroxylated metabolite of PCB11 can inhibit cell proliferation and cause cytotoxicity by increasing steady-state levels of ROS. Furthermore, antioxidant treatments following PCBs exposure could significantly mitigate the PCB-induced cytotoxicity in exponentially growing human prostate epithelial cells. © The Author 2013. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved.
Case A.J.,Holden Comprehensive Cancer Center |
Madsen J.M.,Holden Comprehensive Cancer Center |
Meyerholz D.K.,University of Iowa |
Domann F.E.,Holden Comprehensive Cancer Center
Free Radical Biology and Medicine | Year: 2013
Heme synthesis partially occurs in the mitochondrial matrix; thus there is a high probability that enzymes and intermediates important in the production of heme will be exposed to metabolic by-products including reactive oxygen species. In addition, the need for ferrous iron for heme production, Fe/S coordination, and other processes occurring in the mitochondrial matrix suggests that aberrant fluxes of reactive oxygen species in this compartment might perturb normal iron homeostasis. Manganese superoxide dismutase (Sod2) is an antioxidant enzyme that governs steady-state levels of the superoxide in the mitochondrial matrix. Using hematopoietic stem cell-specific conditional Sod2 knockout mice we observed increased superoxide concentrations in red cell progeny, which caused significant pathologies including impaired erythrocytes and decreased ferrochelatase activity. Animals lacking Sod2 expression in erythroid precursors also displayed extramedullary hematopoiesis and systemic iron redistribution. Additionally, the increase in superoxide flux in erythroid precursors caused abnormal gene regulation of hematopoietic transcription factors, globins, and iron-response genes. Moreover, the erythroid precursors also displayed evidence of global changes in histone posttranslational modifications, a likely cause of at least some of the aberrant gene expression noted. From a therapeutic translational perspective, mitochondrially targeted superoxide-scavenging antioxidants partially rescued the observed phenotype. Taken together, our findings illuminate the superoxide sensitivity of normal iron homeostasis in erythrocyte precursors and suggest a probable link between mitochondrial redox metabolism and epigenetic control of nuclear gene regulation during mammalian erythropoiesis. © 2012 Elsevier Inc.
Welsh J.L.,University of Iowa |
Button A.M.,Holden Comprehensive Cancer Center |
Buettner G.R.,Holden Comprehensive Cancer Center |
Cullen J.J.,University of Iowa |
And 2 more authors.
Cancer Research | Year: 2013
Renewed interest in using pharmacological ascorbate (AscH-) to treat cancer has prompted interest in leveraging its cytotoxic mechanism of action. A central feature of AscH- action in cancer cells is its ability to act as an electron donor to O2 for generating H 2O2. We hypothesized that catalytic manganoporphyrins (MnP) would increase AscH- oxidation rates, thereby increasing H 2O2 fluxes and cytotoxicity. Three different MnPs were tested (MnTBAP, MnT2EPyP, and MnT4MPyP), exhibiting a range of physicochemical and thermodynamic properties. Of the MnPs tested, MnT4MPyP exerted the greatest effect on increasing the rate of AscH- oxidation as determined by the concentration of ascorbate radical [AscH-] and the rate of oxygen consumption. At concentrations that had minimal effects alone, combining MnPs and AscH- synergized to decrease clonogenic survival in human pancreatic cancer cells. This cytotoxic effect was reversed by catalase, but not superoxide dismutase, consistent with a mechanism mediated by H2O2. MnPs increased steady-state concentrations of AscH- upon ex vivo addition to whole blood obtained either from mice infused with AscH- or patients treated with pharmacologic AscH-. Finally, tumor growth in vivo was inhibited more effectively by combining MnT4MPyP with AscH -.Weconcluded that MnPs increase the rate of oxidation of AscH - to leverage H2O2 flux and ascorbateinduced cytotoxicity. © 2013 American Association for Cancer Research.
Navalkele P.,University of Iowa |
O'Dorisio M.S.,Holden Comprehensive Cancer Center |
Zamba G.K.,University of Iowa |
Lynch C.F.,Holden Comprehensive Cancer Center
Pediatric Blood and Cancer | Year: 2011
Background: The incidence, survival, and prevalence of neuroendocrine tumors (NETs) in children were determined as a first step in improving diagnosis and therapy. Outcomes were compared with neuroblastoma, a pediatric malignancy that shares several biomarkers. Methods: Incidence rates, observed survival rates and 31-year limited duration prevalence counts were obtained from SEER*Stat for diagnosis years 1975 to 2006. These rates were compared between and within NETs and neuroblastoma for demographic and tumor-related variables from nine standard SEER registries for ages 0-29 years. Multivariate Cox regression was performed to identify prognostic factors for survival in NETs. Results: The number of NETs was 1,073 compared to 1,664 neuroblastomas. The most common NET sites were lung, breast, and appendix. NET 5-year observed survival rates increased from 83% between 1975 and 1979 to 84% for the 2000-2006 period, while analogous neuroblastoma survival rates steadily increased from 45-73%. Five-year observed survival was less than 30% in females with NETs of the cervix and ovary. The estimated 31-year limited duration prevalence for NETs as of January 1, 2006 in the U.S. population was 7,724 compared to 9,960 for neuroblastomas. Age-adjusted multivariate Cox Regression demonstrated small cell histology, primary location in the breast, and distant stage as major predictors of decreased survival. Conclusions: While survivorship has significantly increased for neuroblastoma, those diagnosed with NETs have shown no increase in survival during this 31-year period. NETs constitute an unrecognized cancer threat to children and young adults comparable to neuroblastoma in both number of affected persons and disease severity. © 2010 Wiley-Liss, Inc.
Allen B.G.,Holden Comprehensive Cancer Center |
Bhatia S.K.,Holden Comprehensive Cancer Center |
Buatti J.M.,Holden Comprehensive Cancer Center |
Brandt K.E.,Holden Comprehensive Cancer Center |
And 6 more authors.
Clinical Cancer Research | Year: 2013
Purpose: Ketogenic diets are high in fat and low in carbohydrates as well as protein which forces cells to rely on lipid oxidation and mitochondrial respiration rather than glycolysis for energy metabolism. Cancer cells (relative to normal cells) are believed to exist in a state of chronic oxidative stress mediated by mitochondrial metabolism. The current study tests the hypothesis that ketogenic diets enhance radiochemo- therapy responses in lung cancer xenografts by enhancing oxidative stress. Experimental Design: Mice bearing NCI-H292 and A549 lung cancer xenografts were fed a ketogenic diet (KetoCal 4:1 fats: proteins+carbohydrates) and treated with either conventionally fractionated (1.8-2 Gy) or hypofractionated (6 Gy) radiation as well as conventionally fractionated radiation combined with carboplatin. Mice weights and tumor size were monitored. Tumors were assessed for immunoreactive 4-hydroxy-2-nonenal-(4HNE)-modified proteins as a marker of oxidative stress as well as proliferating cell nuclear antigen (PCNA) and γH2AX as indices of proliferation and DNA damage, respectively. Results: The ketogenic diets combined with radiation resulted in slower tumor growth in both NCI-H292 and A549 xenografts (P < 0.05), relative to radiation alone. The ketogenic diet also slowed tumor growth when combined with carboplatin and radiation, relative to control. Tumors from animals fed a ketogenic diet in combination with radiation showed increases in oxidative damage mediated by lipid peroxidation as determined by 4HNE-modified proteins as well as decreased proliferation as assessed by decreased immunoreactive PCNA. Conclusions: These results show that a ketogenic diet enhances radio-chemo-therapy responses in lung cancer xenografts by a mechanism that may involve increased oxidative stress. © 2013 American Association for Cancer Research.
Du J.,University of Iowa |
Cullen J.J.,University of Iowa |
Cullen J.J.,Holden Comprehensive Cancer Center |
Cullen J.J.,Veterans Affairs Medical Center |
And 2 more authors.
Biochimica et Biophysica Acta - Reviews on Cancer | Year: 2012
Since the discovery of vitamin C, the number of its known biological functions is continually expanding. Both the names ascorbic acid and vitamin C reflect its antiscorbutic properties due to its role in the synthesis of collagen in connective tissues. Ascorbate acts as an electron-donor keeping iron in the ferrous state thereby maintaining the full activity of collagen hydroxylases; parallel reactions with a variety of dioxygenases affect the expression of a wide array of genes, for example via the HIF system, as well as via the epigenetic landscape of cells and tissues. In fact, all known physiological and biochemical functions of ascorbate are due to its action as an electron donor. The ability to donate one or two electrons makes AscH- an excellent reducing agent and antioxidant. Ascorbate readily undergoes pH-dependent autoxidation producing hydrogen peroxide (H2O2). In the presence of catalytic metals this oxidation is accelerated. In this review, we show that the chemical and biochemical nature of ascorbate contribute to its antioxidant as well as its prooxidant properties. Recent pharmacokinetic data indicate that intravenous (i.v.) administration of ascorbate bypasses the tight control of the gut producing highly elevated plasma levels; ascorbate at very high levels can act as prodrug to deliver a significant flux of H2O2 to tumors. This new knowledge has rekindled interest and spurred new research into the clinical potential of pharmacological ascorbate. Knowledge and understanding of the mechanisms of action of pharmacological ascorbate bring a rationale to its use to treat disease especially the use of i.v. delivery of pharmacological ascorbate as an adjuvant in the treatment of cancer. © 2012.
Cullen J.J.,University of Iowa |
Cullen J.J.,Holden Comprehensive Cancer Center
Autophagy | Year: 2010
Ascorbate (ascorbic acid, vitamin C) is one of the early, unorthodox treatments for cancer. The evidence upon which people base the use of ascorbate in cancer treatment falls into two categories: clinical data on dose concentration relationships, and laboratory data describing potential cell toxicity with high concentrations of ascorbate in vitro. Clinical data show that when ascorbate is given orally, fasting plasma concentrations are tightly controlled by decreased absorption, increased urine excretion, and reduced ascorbate bioavailability. In contrast, when ascorbate is administered intravenously, concentrations in the millimolar level are achieved. Thus, it is clear that intravenous administration of ascorbate can yield very high plasma levels, while oral treatment does not. © 2010 Landes Bioscience.
Shepherd T.R.,University of Iowa |
Fuentes E.J.,University of Iowa |
Fuentes E.J.,Holden Comprehensive Cancer Center
Methods in Enzymology | Year: 2011
Tiam-family guanine exchange proteins are activators of the Rho GTPase Rac1 and critical for cell morphology, adhesion, migration, and polarity. These modular proteins contain a variety of signaling domains, including a single postsynaptic density-95/discs large/zonula occludens-1 (PDZ) domain. Here, we show how structural and thermodynamic approaches applied to the Tiam1 PDZ domain can be used to gain unique insights into the affinity and specificity of PDZ-ligand interactions with peptides derived from Syndecan1 and Caspr4 proteins. First, we describe a fluorescence anisotropy-based assay that can be used to determine PDZ-ligand interactions, and describe important considerations in designing binding experiments. Second, we used site-specific mutagenesis in combination with double-mutant cycle analysis to probe the binding energetics and cooperativity of residues in two ligand binding pockets (S0 and S-2) that are involved in Tiam1 PDZ-ligand interactions. Peptide ligand binding results and double-mutant cycle analysis revealed that the S 0 pocket was important for Syndecan1 and Caspr4 peptide interactions and that the S-2 pocket provided selectivity for the Syndecan1 ligand. Finally, we devised a "peptide evolution" strategy whereby a Model consensus peptide was "evolved" into either the Syndecan1 or Caspr4 peptide by site-directed mutagenesis. These results corroborated the PDZ mutational analysis of the S0 pocket and identified the P -4 position in the ligand as critical for Syndecan1 affinity and selectivity. Together, these studies show that a combined structural and thermodynamic approach is powerful for obtaining insights into the origin of Tiam1 PDZ-ligand domain affinity and specificity. © 2011 Elsevier Inc.